Immuneering Corporation Class A Common Stock H.C. Wainwright 28th Annual Global Investment Conference

Absolutely. Yeah. In terms of where the company is today, we are in phase III with a third generation MEK inhibitor. The phase III is well underway. We have over 40 sites already listed on ClinicalTrials.gov, and that is in first-line pancreatic cancer, which is just a huge unmet need. It is the largest number of patients in pancreatic cancer. We are excited to have that underway. We are excited to have funding through that top line readout, which we have guided to in mid-2028. Now you asked about what some of the misunderstandings may be about the company, and I think there is a number of them, the first one being related to news flow. I think people hear top line readout of the phase III in mid-2028, and maybe they wonder how much is happening between now and then. The reality is quite a bit.

Starting in just a few weeks on September 26th, we have a poster at the AACR Special Conference on Pancreatic Cancer. There we have guided to expanding on the finding that we reported at ASCO this year that 84% of the evaluable patients in our phase II study in first-line pancreatic cancer, were weight stable or gained weight at 3 months. I think that is so important because in pancreatic cancer, patients frequently lose weight. We are going to be expanding on that finding, providing additional context. That is coming up. We have a lung cancer study, a phase II in combination with cemiplimab. We have a supply agreement with Regeneron. We have guided to dosing the first patient in that study by the end of this year and sharing top line results by the end of next year. We have a lot of studies that are ongoing.

I mean, the study that we talked about at ASCO, the 55 patients treated with atebimetinib plus gemcitabine nab-paclitaxel in first-line pancreatic cancer, that study is ongoing. We continue to see that data. Not guiding anything yet. We are still thinking about it, but that is certainly data we have. Similarly, the combination with FOLFIRINOX. Another standard of care treatment in first-line pancreatic cancer, that is another arm of the phase IIa. So far, all we have shared from that is a single case study.

of a patient with a complete response to that combination. That whole arm is ongoing and again, no decisions yet. We're thinking about when to share that. I think there's a misunderstanding about news flow.

Yep. We're going to have a lot.

I think there's a misunderstanding about MEK inhibitors. Historically, the first generation MEK inhibitors got a bad name. They worked in BRAF mutant disease. They didn't work in RAS mutant disease, including pancreatic cancer, and they were quite poorly tolerated. Second generation MEK inhibitors solved the issue of working in RAS mutant disease. That was a good step forward, but they were still pretty toxic. What we did with our third generation MEK inhibitor was, we believe, to solve that second issue of the toxicity.

So, we think MEK has always been a great target. It's just had these two challenges and Yep we think it took three generations to solve it.

But we believe we're there. The paper that we published in July, in Cancer Research top journal.

I think that really laid out how we're a next generation MEK inhibitor. I think some of that baggage from prior generations is misunderstood. Then, look, there's a lot of excitement around RAS these days.

Sure and well there should be.

But I think people mistakenly view RAS inhibition and MEK inhibition as an either/or.

Yep. And the reality is it's both and.

In fact, where the RAS inhibitor field is heading is to mutation-specific RAS inhibitors like G12C inhibitors, KRAS G12D inhibitors, and we've shown preclinical data that demonstrates a lot of synergy.